
Life Science Law Update

walderwyss attorneys at law



We are pleased to send you our latest Life Science Law Update. This newsletter provides monthly news about new laws, decisions and publications related to Life Science Law in Switzerland and in other jurisdictions.

We wish you a pleasant reading.

New Law

Reduction of prices for medicines leads to savings of CHF 100 million

The Federal Office of Public Health has reduced the prices of 257 original preparations as part of its three-year review for 2019.

For further information, see: here.

EMA Q&A on the implementation of the Medical Devices Regulations

EMA's Human Medicines Evaluation Division has released a Q&A document on the implementation of the MDR and IVDR.

For further information, see: here.

Decisions

Federal Supreme Court, Decision 9C_493/2018 of 14 October 2019

The Court held that the Canton of Zurich may not refuse its pro rata remuneration for voluntary extra-cantonal treatment covered by mandatory health care insurance on the basis of the quantity restriction stated for the clinic in question in the hospital list of the Canton of Graubünden.

For further information, see: <u>here</u>.

Federal Administrative Court, Decision C-7112/2017 of 26 September 2019

The Court held that the Federal Council's implementation provisions regarding foreign price comparisons (Auslandpreisvergleich) and regarding therapeutic cross-comparisons (Therapeutischer Quervergleich) comply with the legal requirements of the Health Care Insurance and the principle of equality.

For further information, see: here.

Social Security Court of the Canton of Zurich, Decision KV.2019.00040 of 31 October 2019

The Court approved an appeal against the decision of a health care insurance company rejecting a cost reimbursement request for the off label treatment a patient suffering from a recurrent multiple myeloma.

For further information, see: here.

Publications

Lebensmittel-Compliance: Die strafrechtliche Relevanz des Inverkehrbringens von Hanf in Lebensmitteln

by Isabel Winghofer

in: Compliance Berater 2019, pp. 384 et seg.

Datenschutz und Gesundheitsrecht / Protection des données et droit de la santé by Astrid Epiney and Déborah Sangsue Zurich 2019

Zulassung von Komplementärarzneimitteln im revidierten Heilmittelgesetz

by Claudio Helmle and Lukas Dellenbach

in: Life Science Recht (LSR) 2019, pp. 223 et seq.

VITH und Art. 76a-c KVV, Bemerkungen zu den neuen Verordnungsbestimmungen by Felix Kesselring

in: Life Science Recht (LSR) 2019, pp. 231 et seq.

Publications

Marketing of CBD Products in Switzerland

by Marcel Boller

in: Life Science Recht (LSR) 2019, pp. 248 et seq.

Questions?

Our <u>Life Science Law experts</u> will be happy to answer any questions you may have regarding the content of this e-mail at any time.